Amanda Antell  |  September 12, 2018

Category: Legal News

Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.

Growing MDL Alleges Serious Xarelto Bleeding Risk to PatientsJohnson & Johnson and Bayer HealthCare are facing growing multidistrict litigation (MDL), consisting of product liability claims alleging serious Xarelto bleeding incidents.

One of the most recent claims was filed by a woman from Illinois, who allegedly suffered a Xarelto bleeding incident soon after starting her prescription.

Plaintiff Kimbery L., along with her husband, allege the pharmaceutical companies either knew or should have known about the potential Xarelto bleeding risk, but that this risk was not mentioned on the drug’s label.

Like millions other other patients, Kimberly had been prescribed Xarelto to treat either her atrial fibrillation or to prevent stroke due to the high risk of blood clot formation. Xarelto and other anticoagulants work by inhibiting the body’s clotting mechanism. However, this can also prevent the body from being able to self heal in cases of internal bleeding.

Internal bleeding can quickly become fatal for anticoagulant patients. While a bleeding antidote for Xarelto — Andexxa — was recently approved, the drug still poses a significant risk for uncontrollable Xarelto bleeding.

At the time she was prescribed the drug, Kimberly says had no knowledge of this risk. According to the Xarelto lawsuit, she was prescribed the anticoagulant on July 8, 2013 and had only stayed on the medication until Dec. 3, 2013. However, during the course of her prescription, Kimberly says she suffered a serious Xarelto bleeding incident in October of that year. She says that she and her doctors were not aware that the risk of internal bleeding was higher with the anti-coagulant.

Overview of Xarelto Bleeding Complications

Xarelto was approved by the FDA in 2011, and was the second medication to be approved for anticoagulant purposes in the United States since warfarin in the 1960s. The first new generation anticoagulant, Pradaxa, opened a gateway for other pharmaceuticals to try their hand in the blood thinner market.

Xarelto and other new generation anticoagulants are marketed as more efficient and convenient than warfarin, with their respective companies focusing on their single dose prescription feature.

While patients do not have to frequently see their doctors for dose adjustments, Xarelto and other new generation anticoagulants put patients at risk for uncontrollable internal bleeding allege patient who took the drugs instead of warfarin.

Until the release of Pradaxa’s reversal agent Praxbind in 2015, warfarin had been the only major anticoagulant with an approved reversal agent to stop internal bleeding incidents.

While Kimberly survived her ordeal, she states that the risk of Xarelto bleeding is unreasonable to patients and should have been included in the product information presented by Bayer and Johnson & Johnson. During all times relevant, Kimberly and her physician had relied on the marketing statements of both companies.

Kimberly states that she would not have agreed to take medication, if she had known the risk of Xarelto bleeding injuries.

Kimberly’s Xarelto lawsuit is joining MDL No. 2592, where it will stand alongside other claims alleging similar Xarelto bleeding incidents. By joining an MDL, Kimberly’s claim will be streamlined through the litigation process and will avoid potential problems like conflicting rulings from different judges.

Kimberly is seeking a multitude of damages in her Xarelto lawsuit based on counts of negligence and failure to warn.

This Xarelto Lawsuit is Case No. 2:18-cv-07490-EEF-MBN, in the U.S. District Court of Eastern Louisiana.

Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.

Learn More

We tell you about cash you can claim EVERY WEEK! Sign up for our free newsletter.


Get Help – It’s Free

Join a Free Xarelto Class Action Lawsuit Investigation

If you or a loved one took Xarelto (rivaroxaban) and suffered injuries such as uncontrollable internal bleeding, gastrointestinal bleeding, hemorrhaging, deep vein thrombosis or pulmonary embolism, you may have a legal claim. See if you qualify by filling out the short form below.

An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.

PLEASE NOTE: If you want to participate in this investigation, it is imperative that you reply to the law firm if they call or email you. Failing to do so may result in you not getting signed up as a client or getting you dropped as a client.

Oops! We could not locate your form.

Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.